Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

Healthcare Biotechnology
iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Satellos Bioscience Inc Com
Bullboard Posts
User Avatar Image
(0)
•••
Post by pool1212on Jan 03, 2013 7:12am
266 Views
Post# 20791539

iCo Therapeutics Announces Positive iCo-007 Phase

iCo Therapeutics Announces Positive iCo-007 Phase

 

latest news release - looks pretty good and much in line with phase I and expectations might also appear higher moving forward in light of higher participation rate.

https://www.newswire.ca/en/story/1094927/ico-therapeutics-announces-positive-ico-007-phase-2-clinical-update

there are links within the article to the clinical trials site but have also added below for reference

https://www.clinicaltrials.gov/ct2/show/NCT01565148?term=iCo-007&rank=2

links to ideal study website as well

https://idealstudy.org/

regards

 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities